JP2008513405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513405A5 JP2008513405A5 JP2007531711A JP2007531711A JP2008513405A5 JP 2008513405 A5 JP2008513405 A5 JP 2008513405A5 JP 2007531711 A JP2007531711 A JP 2007531711A JP 2007531711 A JP2007531711 A JP 2007531711A JP 2008513405 A5 JP2008513405 A5 JP 2008513405A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidinyl
- methyl
- alkyl
- methylethyl
- cyclobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 7
- -1 5- {4-[(1-cyclobutyl-4-piperidinyl) methyl] -1-piperidinyl} -2-pyridinecarboxylic acid hydrochloride Chemical compound 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- GSGFPGAEHOFDPV-UHFFFAOYSA-N 1-[4-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]-2,2,2-trifluoroethanone Chemical compound C1=CC(C(=O)C(F)(F)F)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 GSGFPGAEHOFDPV-UHFFFAOYSA-N 0.000 claims 1
- JXDITEKFBWFLLS-UHFFFAOYSA-N 1-[4-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 JXDITEKFBWFLLS-UHFFFAOYSA-N 0.000 claims 1
- UCPDJKHTNBJISS-UHFFFAOYSA-N 1-[4-[4-[(1-ethylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]ethanone Chemical compound C1CN(CC)CCC1CC1CCN(C=2C=CC(=CC=2)C(C)=O)CC1 UCPDJKHTNBJISS-UHFFFAOYSA-N 0.000 claims 1
- AFMJVPLQQBTRFN-UHFFFAOYSA-N 1-[4-[4-[(1-methylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]ethanone Chemical compound C1CN(C)CCC1CC1CCN(C=2C=CC(=CC=2)C(C)=O)CC1 AFMJVPLQQBTRFN-UHFFFAOYSA-N 0.000 claims 1
- CZJWVSHDNBSENK-UHFFFAOYSA-N 1-[4-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]ethanone Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=CC(=CC=2)C(C)=O)CC1 CZJWVSHDNBSENK-UHFFFAOYSA-N 0.000 claims 1
- ULBXCFSIFQJEQV-UHFFFAOYSA-N 1-[4-[4-[[1-(cyclopropylmethyl)piperidin-4-yl]methyl]piperidin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCC(CC2CCN(CC3CC3)CC2)CC1 ULBXCFSIFQJEQV-UHFFFAOYSA-N 0.000 claims 1
- YNUMGPGJIZSXSX-UHFFFAOYSA-N 1-[5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-2-yl]ethanone Chemical compound C1=NC(C(=O)C)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 YNUMGPGJIZSXSX-UHFFFAOYSA-N 0.000 claims 1
- XESYQFVZWPXMEF-UHFFFAOYSA-N 1-[5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-2-yl]ethanone Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=NC(=CC=2)C(C)=O)CC1 XESYQFVZWPXMEF-UHFFFAOYSA-N 0.000 claims 1
- SHKCFQVJQJJJJW-UHFFFAOYSA-N 1-[6-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-3-yl]ethanone Chemical compound N1=CC(C(=O)C)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 SHKCFQVJQJJJJW-UHFFFAOYSA-N 0.000 claims 1
- YRTZPTVSZHFDEY-UHFFFAOYSA-N 1-[6-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-3-yl]ethanone Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2N=CC(=CC=2)C(C)=O)CC1 YRTZPTVSZHFDEY-UHFFFAOYSA-N 0.000 claims 1
- UAIVAUOJPSJQDH-UHFFFAOYSA-N 3-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-6-(trifluoromethyl)pyridazine Chemical compound N1=NC(C(F)(F)F)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 UAIVAUOJPSJQDH-UHFFFAOYSA-N 0.000 claims 1
- UNVRCIYSLCUMOB-UHFFFAOYSA-N 3-methyl-5-[4-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]-1,2,4-oxadiazole Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=CC(=CC=2)C=2ON=C(C)N=2)CC1 UNVRCIYSLCUMOB-UHFFFAOYSA-N 0.000 claims 1
- PFMNQJRTADLGGT-UHFFFAOYSA-N 3-methyl-5-[5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-2-yl]-1,2,4-oxadiazole Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=NC(=CC=2)C=2ON=C(C)N=2)CC1 PFMNQJRTADLGGT-UHFFFAOYSA-N 0.000 claims 1
- PQQIDKJXTQPNSK-UHFFFAOYSA-N 5-[2-fluoro-4-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=C(F)C(C=3ON=C(C)N=3)=CC=2)CC1 PQQIDKJXTQPNSK-UHFFFAOYSA-N 0.000 claims 1
- KWOGQINTOGSLFN-UHFFFAOYSA-N 5-[3-fluoro-4-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C(=CC(=CC=2)C=2ON=C(C)N=2)F)CC1 KWOGQINTOGSLFN-UHFFFAOYSA-N 0.000 claims 1
- KPRASRCQBQNYCU-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-2-(trifluoromethyl)pyrimidine Chemical compound C1=NC(C(F)(F)F)=NC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 KPRASRCQBQNYCU-UHFFFAOYSA-N 0.000 claims 1
- CMAQNUSSBJKQOA-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-n-ethylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NCC)=CN=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 CMAQNUSSBJKQOA-UHFFFAOYSA-N 0.000 claims 1
- YVORDKMQWSIKJB-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 YVORDKMQWSIKJB-UHFFFAOYSA-N 0.000 claims 1
- JMFMUYSGFMKHHG-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 JMFMUYSGFMKHHG-UHFFFAOYSA-N 0.000 claims 1
- CFAFAIASRGBKNN-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]-n-propan-2-ylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CN=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 CFAFAIASRGBKNN-UHFFFAOYSA-N 0.000 claims 1
- SEAMETQZVVSBAG-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyrazine-2-carboxylic acid;hydrochloride Chemical compound Cl.C1=NC(C(=O)O)=CN=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 SEAMETQZVVSBAG-UHFFFAOYSA-N 0.000 claims 1
- FRWCBKJOSQVOOJ-UHFFFAOYSA-N 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 FRWCBKJOSQVOOJ-UHFFFAOYSA-N 0.000 claims 1
- GIDQEHZBYYQURN-UHFFFAOYSA-N 5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyridine-2-carbonitrile Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=NC(=CC=2)C#N)CC1 GIDQEHZBYYQURN-UHFFFAOYSA-N 0.000 claims 1
- WYJAFEMOKMNDPM-UHFFFAOYSA-N 5-[4-[4-[[1-(cyclopropylmethyl)piperidin-4-yl]methyl]piperidin-1-yl]phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=CC(=CC=2)N2CCC(CC3CCN(CC4CC4)CC3)CC2)=N1 WYJAFEMOKMNDPM-UHFFFAOYSA-N 0.000 claims 1
- FCQBKRBJRHKGOV-UHFFFAOYSA-N 5-[5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyridin-2-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2N=CC(=CC=2)N2CCC(CC3CCN(CC3)C3CCC3)CC2)=N1 FCQBKRBJRHKGOV-UHFFFAOYSA-N 0.000 claims 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 1
- OBOLYNQLHKRMQA-UHFFFAOYSA-N C1=CC=C(C=C1)ON(C(=O)C2=CC=CC=C2OS(=O)(=O)C3=CC=CC=C3)NS(=O)(=O)C4=CC=CC=C4 Chemical compound C1=CC=C(C=C1)ON(C(=O)C2=CC=CC=C2OS(=O)(=O)C3=CC=CC=C3)NS(=O)(=O)C4=CC=CC=C4 OBOLYNQLHKRMQA-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- ZAZJSJFQRJUTAM-UHFFFAOYSA-N methyl 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyrazine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CN=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 ZAZJSJFQRJUTAM-UHFFFAOYSA-N 0.000 claims 1
- JVKYGIDHSJKVLD-UHFFFAOYSA-N methyl 5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyrazine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CN=C1N1CCC(CC2CCN(CC2)C(C)C)CC1 JVKYGIDHSJKVLD-UHFFFAOYSA-N 0.000 claims 1
- HQWBBOSFFWMGDV-UHFFFAOYSA-N n-propan-2-yl-5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CN=C1N1CCC(CC2CCN(CC2)C(C)C)CC1 HQWBBOSFFWMGDV-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- SLLOIKKWMOLTEF-UHFFFAOYSA-N tert-butyl 5-[4-[(1-cyclobutylpiperidin-4-yl)methyl]piperidin-1-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC(C)(C)C)=CC=C1N1CCC(CC2CCN(CC2)C2CCC2)CC1 SLLOIKKWMOLTEF-UHFFFAOYSA-N 0.000 claims 1
- WVNSMDASXXXKQL-UHFFFAOYSA-N tert-butyl 5-[4-[(1-propan-2-ylpiperidin-4-yl)methyl]piperidin-1-yl]pyridine-2-carboxylate Chemical compound C1CN(C(C)C)CCC1CC1CCN(C=2C=NC(=CC=2)C(=O)OC(C)(C)C)CC1 WVNSMDASXXXKQL-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0420831A GB0420831D0 (en) | 2004-09-17 | 2004-09-17 | Novel compounds |
| PCT/EP2005/010169 WO2006029906A1 (en) | 2004-09-17 | 2005-09-16 | Methylene dipiperidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513405A JP2008513405A (ja) | 2008-05-01 |
| JP2008513405A5 true JP2008513405A5 (US06653308-20031125-C00057.png) | 2008-10-16 |
Family
ID=33306857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531711A Withdrawn JP2008513405A (ja) | 2004-09-17 | 2005-09-16 | メチレンジピペリジン誘導体 |
Country Status (8)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| CN103382174A (zh) | 2006-06-23 | 2013-11-06 | 雅培制药有限公司 | 作为组胺h3受体调节物的环丙胺衍生物 |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| BRPI0923051B1 (pt) | 2008-12-19 | 2022-07-19 | Centrexion Therapeutics Corporation | Pirimidin-4-carboxamidas cíclicas como antagonistas do receptor de ccr2 para o tratamento de inflamação, asma e copd, seu uso, formulação e combinação farmacêutica que os compreende |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2011029633A1 (en) * | 2009-09-14 | 2011-03-17 | Recordati Ireland Limited | Heterocyclic mglu5 antagonists |
| KR101530234B1 (ko) | 2009-12-17 | 2015-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 ｃｃｒ２ 수용체 길항제 및 이의 용도 |
| AU2011212951A1 (en) * | 2010-02-04 | 2012-08-23 | Flsmidth A/S | Method for treating tailings |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体アンタゴニスト |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN108026087B (zh) | 2015-07-02 | 2021-06-04 | 中枢疗法公司 | 氨基嘧啶甲酮衍生物的柠檬酸盐 |
| EP3383853B1 (en) | 2015-12-01 | 2020-11-04 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0418071A (ja) | 1990-05-11 | 1992-01-22 | Sumitomo Pharmaceut Co Ltd | ビスピペリジン誘導体 |
| EA200000768A1 (ru) | 1998-01-27 | 2001-06-25 | Эвентис Фармасьютикалз Продактс Инк. | ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха |
| YU71101A (sh) | 1999-04-01 | 2004-07-15 | Pfizer Products Inc. | Aminopirimidini kao inhibitori sorbitol dehidrogenaze |
| PL354998A1 (en) | 1999-07-28 | 2004-03-22 | Aventis Pharmaceuticals Products Inc. | Substituted oxoazaheterocyclyl compounds |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| DE60106968T2 (de) | 2000-11-30 | 2005-11-03 | Pfizer Products Inc., Groton | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren |
| CA2436083A1 (en) | 2001-02-08 | 2002-09-19 | Schering Corporation | Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders |
| US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
| US6956040B2 (en) * | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
| WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
-
2004
- 2004-09-17 GB GB0420831A patent/GB0420831D0/en not_active Ceased
-
2005
- 2005-09-16 JP JP2007531711A patent/JP2008513405A/ja not_active Withdrawn
- 2005-09-16 EP EP05789636A patent/EP1789410B1/en active Active
- 2005-09-16 US US11/575,311 patent/US7638631B2/en not_active Expired - Fee Related
- 2005-09-16 WO PCT/EP2005/010169 patent/WO2006029906A1/en active Application Filing
- 2005-09-16 DE DE602005015002T patent/DE602005015002D1/de active Active
- 2005-09-16 AT AT05789636T patent/ATE433966T1/de not_active IP Right Cessation
- 2005-09-16 ES ES05789636T patent/ES2326182T3/es active Active
